新型冠状病毒肺炎与抗血小板治疗反应
COVID-19 and the Response to Antiplatelet Therapy.
作者信息
Bolek Tomáš, Samoš Matej, Jurica Jakub, Stančiaková Lucia, Péč Martin Jozef, Škorňová Ingrid, Galajda Peter, Staško Ján, Mokáň Marián, Kubisz Peter
机构信息
Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, Slovakia.
National Centre of Hemostasis and Thrombosis, Department of Hematology and Blood, Transfusion, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, Slovakia.
出版信息
J Clin Med. 2023 Mar 4;12(5):2038. doi: 10.3390/jcm12052038.
The coronavirus SARS-CoV2 disease (COVID-19) is connected with significant morbidity and mortality (3.4%), disorders in hemostasis, including coagulopathy, activation of platelets, vascular injury, and changes in fibrinolysis, which may be responsible for an increased risk of thromboembolism. Many studies demonstrated relatively high rates of venous and arterial thrombosis related to COVID-19. The incidence of arterial thrombosis in severe/critically ill intensive care unit-admitted COVID-19 patients appears to be around 1%. There are several ways for the activation of platelets and coagulation that may lead to the formation of thrombi, so it is challenging to make a decision about optimal antithrombotic strategy in patients with COVID-19. This article reviews the current knowledge about the role of antiplatelet therapy in patients with COVID-19.
冠状病毒SARS-CoV2疾病（COVID-19）与显著的发病率和死亡率（3.4%）、止血障碍有关，包括凝血病、血小板活化、血管损伤以及纤维蛋白溶解的变化，这些可能是血栓栓塞风险增加的原因。许多研究表明，与COVID-19相关的静脉和动脉血栓形成率相对较高。入住重症监护病房的重症/危重症COVID-19患者的动脉血栓形成发生率似乎约为1%。血小板活化和凝血有多种途径可能导致血栓形成，因此，对于COVID-19患者的最佳抗栓策略做出决策具有挑战性。本文综述了关于抗血小板治疗在COVID-19患者中作用的当前知识。
Zotero 插件